Sequenom has appointed John Fazio to its board of directors. Fazio, who also will serve as chairman of the firm’s audit committee, formerly was senior general practice partner at PricewaterhouseCoopers, where he had a 35-year career.
Charles Harwood, Tim Derrington, John Sluis, John Fazio
Nov 07, 2007
BioReliance has named Charles Harwood, who currently is executive chairman, to the post of interim CEO in the wake of the departure of former CEO Tim Derrington.
BioReliance, which Invitrogen sold in April to Avista Capital Partners for $210 million, noted that since June three senior executives have joined the company, including David Onions as CSO, David Walker as CFO, and Darryl Goss as VP of Global Process Excellence.
Harwood formerly was president and CEO of Focus Diagnostics and was SVP of venture development at Covance.
Cepheid CFO John Sluis will retire on Dec. 31, the company said in its quarterly earnings statement this week. The company is seeking a replacement for Sluis, who will remain a consultant for Cepheid through 2008. Sluis joined Cepheid as VP of finance and CFO.